<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29482422</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>Jun</Month><Day>03</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation.</ArticleTitle><Pagination><StartPage>1517</StartPage><EndPage>1523</EndPage><MedlinePgn>1517-1523</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2018.1442997</ELocationID><Abstract><AbstractText>The longevity of antibodies induced by inactivated enterovirus 71 type (EV71) vaccine is not well studied. To estimate the immunity persistence following two-dose vaccination of EV71 vaccine, a five-year follow-up study was conducted as an extension of a Phase III clinical trial. In this study, a sub-cohort of volunteers who was eligible for enrollment and randomly administrated either 2 dose EV71 vaccine or placebo in the phase III clinical trial was selected, and then further observed 64&#xa0;months post the 1st vaccination. 211 Subjects (106 vaccine subjects and 105 placebo subjects) who provided a full series of blood samples (at all the sampling points) were included in the final analyzed population. Seropositive rate (SR) and geometric mean titer (GMT) of the neutralizing antibodies (NAb) was calculated to detect the dynamic profiles of EV71 vaccine-induced immunogenicity. SR at the 5th year remained 94.34% in the vaccine subjects, with a GMT of 141.42. The SR was 71.43% in the placebo subjects, with a GMT of 71.83. Despite natural infection consistently promoted the NAb increase in the placebo subjects, the SR and GMT in vaccine subjects remained significantly higher than that in the placebo subjects at all the sampling points. The inactivated EV71 vaccine-induced immunity had a good persistence, within 5&#xa0;years following the primary vaccination.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yuemei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>a Jiangsu Province Center for Disease Control and Prevention , Nanjing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>b Sinovac Biotech Co., LTD. , Beijing , China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>c Beijing Engineering Research Center , Beijing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>a Jiangsu Province Center for Disease Control and Prevention , Nanjing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>d Sheyang County Center for Disease Control and Prevention , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Weixiao</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>b Sinovac Biotech Co., LTD. , Beijing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>b Sinovac Biotech Co., LTD. , Beijing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>b Sinovac Biotech Co., LTD. , Beijing , China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Fengcai</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>a Jiangsu Province Center for Disease Control and Prevention , Nanjing , China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03281174</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">children</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">inactivated enterovirus 71 type vaccine</Keyword><Keyword MajorTopicYN="N">neutralizing antibody</Keyword><Keyword MajorTopicYN="N">persistence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>4</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29482422</ArticleId><ArticleId IdType="pmc">PMC6037439</ArticleId><ArticleId IdType="doi">10.1080/21645515.2018.1442997</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nasri D, Bouslama L, Pillet S, Bourlet T, Aouni M, Pozzetto B. Basic rationale, current methods and future directions for molecular typing of human enterovirus. Expert Rev Mol Diagn. 2007;7(4):419&#x2013;34 doi:10.1586/14737159.7.4.419. PMID:17620049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737159.7.4.419</ArticleId><ArticleId IdType="pubmed">17620049</ArticleId></ArticleIdList></Reference><Reference><Citation>Abubakar S, Chee HY, Alkobaisi MF, Xiaoshan J, Chua KB, Lam SK. Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. Virus Res. 1999;61(1):1&#x2013;9 doi:10.1016/S0168-1702(99)00019-2. PMID:10426204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-1702(99)00019-2</ArticleId><ArticleId IdType="pubmed">10426204</ArticleId></ArticleIdList></Reference><Reference><Citation>Shekhar K, Lye MS, Norlijah O, Ong F, Looi LM, Khuzaiah R, Marzuki I, Hussein I, Wong SL, Mohan J. Deaths in children during an outbreak of hand, foot and mouth disease in Peninsular Malaysia&#x2013;clinical and pathological characteristics. Med J Malaysia. 2005;60(3):297&#x2013;304 PMID:16379183.</Citation><ArticleIdList><ArticleId IdType="pubmed">16379183</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert GL, Dickson KE, Waters MJ, Kennett ML, Land SA, Sneddon M. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J. 1988;7(7):484&#x2013;8 doi:10.1097/00006454-198807000-00007. PMID:2841639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-198807000-00007</ArticleId><ArticleId IdType="pubmed">2841639</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Lv H, Zhu W, Mo Z, Mao G, Wang X, Lou X, Chen Y. Epidemiologic features of enterovirus 71-associated hand-foot-and-mouth disease from 2009 to 2013 in Zhejiang, China. Inter J Env Res Pub Heal. 2017;14(1):33</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5295284</ArticleId><ArticleId IdType="pubmed">28042848</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Qian Y, Wang S, Serrano JM, Li W, Huang Z, Lu S. EV71: an emerging infectious disease vaccine target in the Far East? Vaccine. 2010;28(20):3516&#x2013;21 doi:10.1016/j.vaccine.2010.03.003. PMID:20304038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.03.003</ArticleId><ArticleId IdType="pubmed">20304038</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcminn P, Lindsay K, Perera D, Chan HM, Chan KP, Cardosa MJ. Phylogenetic analysis of enterovirus 71 strains isolated during linked epidemics in Malaysia, Singapore, and Western Australia. J Virol. 2001;75(16):7732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC115010</ArticleId><ArticleId IdType="pubmed">11462047</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, Ho KK, Han LL, Pallansch MA, Suleiman AB. Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis. 2000;31(3):678 doi:10.1128/JVI.75.16.7732-7738.2001. doi:10.1086/314032. PMID:11462047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.16.7732-7738.2001</ArticleId><ArticleId IdType="doi">10.1086/314032</ArticleId><ArticleId IdType="pubmed">11017815</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua KB, Chua BH, Lee CS, Chem YK, Ismail N, Kiyu A, Kumarasamy V. Genetic diversity of enterovirus 71 isolated from cases of hand, foot and mouth disease in the 1997, 2000 and 2005 outbreaks, Peninsular Malaysia. Malays J of Pathol. 2007;29(2):69&#x2013;78</Citation><ArticleIdList><ArticleId IdType="pubmed">19108398</ArticleId></ArticleIdList></Reference><Reference><Citation>An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999;341(13):929&#x2013;35 doi:10.1056/NEJM199909233411301. PMID:10498487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Chow VT, Phoon MC, Chan KP, Poh CL. Direct detection of enterovirus 71 (EV71) in clinical specimens from a hand, foot, and mouth disease outbreak in Singapore by reverse transcription-PCR with universal enterovirus and EV71-specific primers. J Clin Microbiol. 2002;40(8):2823&#x2013;7 doi:10.1128/JCM.40.8.2823-2827.2002. PMID:12149336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.40.8.2823-2827.2002</ArticleId><ArticleId IdType="pmc">PMC120643</ArticleId><ArticleId IdType="pubmed">12149336</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu PV, Thao NT, Perera D, Huu TK, Tien NT, Thuong TC, How OM, Cardosa MJ, Mcminn PC. Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis. 2007;13(11):1733&#x2013;41 doi:10.3201/eid1311.070632. PMID:18217559.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1311.070632</ArticleId><ArticleId IdType="pmc">PMC3375788</ArticleId><ArticleId IdType="pubmed">18217559</ArticleId></ArticleIdList></Reference><Reference><Citation>Huu KT, Saraswathy S, Tan TT, Kim TLP, Chi TT, Hang VTT, Jeremy F, Tinh HT, Vinh CNV, Rogier VDH. Enterovirus 71&#x2013;associated hand, foot, and mouth disease, Southern Vietnam, 2011. Emerg Infect Dis. 2012;18(12):2002&#x2013;5 doi:10.3201/eid1812.120929. PMID:23194699.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1812.120929</ArticleId><ArticleId IdType="pmc">PMC3557876</ArticleId><ArticleId IdType="pubmed">23194699</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Z, Zhen Z, Yang W, Ren J, Tan X, Yu W, Mao N, Xu S, Zhu S, Cui A. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of Hand Foot and Mouth Disease in Fuyang city of China. Virol J. 2010;7(1):94&#x2013;102 doi:10.1186/1743-422X-7-94. PMID:20459851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-94</ArticleId><ArticleId IdType="pmc">PMC2885340</ArticleId><ArticleId IdType="pubmed">20459851</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Ren L, Xiong Z, Li J, Xiao Y, Zhao R, He Y, Bu G, Zhou S, Wang J. Enterovirus 71 Outbreak in the People's Republic of China in 2008. J Clin Microbiol. 2009;47(7):2351&#x2013;2 doi:10.1128/JCM.00563-09. PMID:19439545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00563-09</ArticleId><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, Liu Y, Yin WD, Li RC, Wang JZ. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine. 2012;30(22):3295&#x2013;303 doi:10.1016/j.vaccine.2012.03.010. PMID:22426327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.03.010</ArticleId><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Xia JL, Wu JY, Wang L, Song LF, Mao QY, Wen SQ, Huang RG, Hu YS. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 Vaccine: A Phase II, randomized, double-blind, placebo-controlled trial. J Infect Dis. 2014;209(1):46&#x2013;55 doi:10.1093/infdis/jit429. PMID:23922377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit429</ArticleId><ArticleId IdType="pubmed">23922377</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. New Engl J Med. 2014;370(9):818&#x2013;28 doi:10.1056/NEJMoa1304923. PMID:24571754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JX, Song YF, Wang L, Zhang XF, Hu YS, Hu YM, Xia JL, Li J, Zhu FC. Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Rev Vaccines. 2016;15(1):129&#x2013;37 doi:10.1586/14760584.2016.1096782. PMID:26460695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1096782</ArticleId><ArticleId IdType="pubmed">26460695</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Mo Z, Liang Z, Zhang Y, Li R, Ong KC, Wong KT, Yang E, Che Y, Wang J. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations. BMC Med. 2015;13(1):1&#x2013;10 doi:10.1186/s12916-015-0448-7. PMID:25563062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-015-0448-7</ArticleId><ArticleId IdType="pmc">PMC4574357</ArticleId><ArticleId IdType="pubmed">26381232</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai B, Chen ZH, Liu QC, Wu T, Guo CY, Wang XZ, Fang HH, Xiang YZ. Duration of immunity following immunization with live measles vaccine: 15&#xa0;years of observation in Zhejiang Province, China. Bull World Health Organ. 1991;69(4):415&#x2013;23 PMID:1934235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2393239</ArticleId><ArticleId IdType="pubmed">1934235</ArticleId></ArticleIdList></Reference><Reference><Citation>Musher DM, Manoff SB, Liss C, Mcfetridge RD, Marchese RD, Bushnell B, Alvarez F, Painter C, Blum MD, Silber JL. Safety and antibody response, including antibody persistence for 5&#xa0;years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis. 2010;201(4):516&#x2013;24 doi:10.1086/649839. PMID:20092407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/649839</ArticleId><ArticleId IdType="pubmed">20092407</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007;25(21):4324&#x2013;33 doi:10.1016/j.vaccine.2007.02.069. PMID:17445955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2007.02.069</ArticleId><ArticleId IdType="pubmed">17445955</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Liang Y, Lin HM, Zhang ZY, Che Y, Liao Y, Sheng JF, Zhao ZM, Cui PF, Long RX, et&#xa0;al.. Dynamic monitoring of anti-poliovirus neutralizing antibody and anti-hepatitis A virus IgG antibody in healthy children immunized with inactivated enterovirus 71 vaccine (human diploid cell). Chin J Micro Immun. 2017;37(4):290&#x2013;6. (in Chinese)</Citation></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, et&#xa0;al.. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381(9882):2024&#x2013;32 doi:10.1016/S0140-6736(13)61049-1. PMID:23726161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Zhu SL, Liu YM, Li RC, Yin DP, Xia W, Li YP, Qi ZJ, Wang DY, Li XL. Enterovirus type 71 neutralizing antibody levels among children 0&#x2013;15&#xa0;years old in four counties of Guangxi Zhuang Autonomous region. Chin J Vacc and Immun. 2015;21(3):273&#x2013;7.(in Chinese)</Citation></Reference><Reference><Citation>Li ZF, Liu TX, Yang GP, Xia XT. Serum epidemiology survey of EV71 in children in Lipu county of Guangxi province in 2010. J Appl Prev Med. 2013;19(5):281&#x2013;3.(in Chinese)</Citation></Reference><Reference><Citation>Ding Q, Zhu FC, LI L, Li DH, Liu YM. Serum epidemiology survey of HEV 71 among children in Ganyu county. J J Prev Med. 2011;22(5):4&#x2013;6. (in Chinese)</Citation></Reference><Reference><Citation>Ooi EE, Phoon MC, Ishak B, Chan SH. Seroepidemiology of human enterovirus 71, Singapore. Emerg Infect Dis. 2002;8(9):995&#x2013;7 doi:10.3201/eid0809.010397. PMID:12194783.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0809.010397</ArticleId><ArticleId IdType="pmc">PMC2732542</ArticleId><ArticleId IdType="pubmed">12194783</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang ZR, Liu FF, Lv B, Wang ZC, Zeng LJ, Li ZJ, Liao QH. Analysis on surveillance data of hand, foot and mouth disease in China, January-May. Dis Surveil. 2017;32(6):447&#x2013;52. (in Chinese)</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>